Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)

Bilim, Vladimir; Hoshi, Senji

doi:10.1002/ccr3.5256

Cited by 4 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, nearly 50%-80% of patients experienced bladder tumor recurrence after transurethral resection. 19 The main forms of recurrence after NMIBC resection are in situ recurrence and ectopic recurrence, among which ectopic recurrence is more common. Thus, more efficient and thorough treatment methods with a higher safety profile are needed.…”

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Li¹,

Wang²,

Zhi-hu³

2022

CMAR

View full text Add to dashboard Cite

Objective Bladder cancer is a common malignant tumor of the urinary system, with an incidence ranking the first in the urinary system. Without timely and effective treatment, the tumor may spread to other parts of the body. Traditional partial cystectomy (PC) and plasmakinetic transurethral resection of bladder tumor (PKRBT) are common surgical methods for superficial bladder cancer (SBC). This study aims to clarify the clinical efficacy of bladder carcinoma (BC) patients treated by either PC or PKRBT and their effects on the quality of life (QOL) of patients. Methods A total of 142 patients with SBC treated in Wenzhou Central Hospital and Bei da huang Industry Group General Hospital from March 2018 to June 2020 were analyzed retrospectively. According to the surgical method, patients undergoing PKRBT were included in the research group (n = 74) while those treated by PC were included in the control group (n = 69). Surgical indicators (intraoperative blood loss, IBL; operating time, OT; bladder irrigation time; catheter retention time; length of hospital stay, LOS), postoperative complication rate, and one-year recurrence rate were compared between the two groups. Besides, the levels of inflammatory factors [tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-10], psychological and emotional scores (Self-Rating Anxiety Scale, SAS; Self-Rating Depression Scale, SDS), and living conditions (Pittsburgh Sleep Quality Index, PSQI) before and after treatment were compared. Results Compared with the control group, patients in the research group had 1) less IBL, less time of OT, bladder irrigation and indwelling catheter time, as well as shorter postoperative LOS; 2) lower contents of inflammatory factors TNF-α, IL-6 and IL-8, and higher IL-10; 3) lower SAS and SDS scores and higher PSQI; and 4) fewer postoperative complications and lower one-year recurrence rate. Conclusion Compared with PC, PKRBT contributes to higher efficacy and better postoperative QOL in patients SBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Li¹,

Wang²,

Zhi-hu³

2022

CMAR

View full text Add to dashboard Cite

show abstract

Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics

Xue,

Zhuang,

Peng

et al. 2024

Abdom Radiol

View full text Add to dashboard Cite

Prostatic urethra recurrence after transurethral resection of bladder tumor (TURBT) for non‐muscle‐invasive bladder cancer (NMIBC)

Cited by 4 publications

References 25 publications

Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Clinical Efficacy and Quality of Life Assessment of Partial Cystectomy and Plasmakinetic Transurethral Resection of Tumor in Bladder Cancer Patients

Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics

The expression of SLFN11 is related to the sensitivity of bladder cancer cells to DNA damage agents

Contact Info

Product

Resources

About